HOME Research Insight Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland) and Alere Inc. (U.S.) are Largest Players in Influenza Diagnostics Market.



Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland) and Alere Inc. (U.S.) are Largest Players in Influenza Diagnostics Market.


The prominent players in the influenza diagnostics market include F. Hoffmann-La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), Alere Inc. (U.S.), Luminex Corporation (U.S.), Quidel Corporation (U.S.), Analytik Jena AG (Germany), Meridian Bioscience, Inc. (U.S.), DiaSorin S.p.A. (Italy), and SA Scientific, Ltd. (U.S.).

Thermo Fisher Scientific Inc. (U.S.) is the largest player in the global influenza diagnostics market. To remain competitive, the company adopted inorganic and organic growth strategies such as acquisitions, collaborations, and expansions for enhancing its presence in the market. For instance, in March 2016, the company acquired Affymetrix, Inc. (U.S.), a pioneer in microarrays and genomic analysis. The acquisition provided the company with technologies and systems that allow multiplex and parallel analysis of biological systems at the cellular, protein, and genetic levels. This acquisition strengthened the company’s molecular diagnostics portfolio. Similarly, in October 2014, the company opened a new manufacturing facility in Fremont, California. The facility focuses on the development of innovative technologies for diagnostic testing and quality controls used in healthcare and other markets. This expansion strengthened the company’s diagnostics product portfolio.

F. Hoffmann-La Roche AG (Switzerland) is the second largest player in the global influenza diagnostics market. The company focuses on organic growth strategies such as approvals to sustain its foothold in the market. For instance, in August 2016, Roche Diagnostics, a subsidiary of F. Hoffmann-La Roche AG, received 510(k) clearance and CLIA (Clinical Laboratory Improvement Amendments) waiver from the FDA for Cobas Influenza A/B & RSV tests. The test is based on real-time PCR technology and is used for the detection and differentiation of Influenza A, Influenza B, and respiratory syncytial virus in 20 minutes. This approval strengthened the company’s influenza diagnostics product portfolio. Similarly, in September 2015, the company received CLIA waiver from the FDA for Cobas Influenza A/B Assay, the first CLIA-waived real-time PCR test. With this approval, the company enhanced its influenza product portfolio.

Alere Inc. (U.S.) is the third largest player in the global influenza diagnostics market. The company focuses on organic strategies such as approvals to garner higher revenues in the market. For instance, in January 2015, the company received CLIA waiver approval for Alere i Influenza A & B test from the FDA. The new test detects and differentiates influenza A and B virus in 15 minutes. Based on innovative molecular technology, the new test provides accurate results in 15 minutes. This enhanced the company’s influenza diagnostics product portfolio.

Related Reports:

Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021

Contact:
Mr.Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports